EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Remimazolam for sedation and anesthesia in children: A scoping review

Vladimir Kuklin iD, Tom G Hansen iD

Acta Anaesthesiologica Scandinavica · 2024-08 · 68 (7) · 862-870

DOI: 10.1111/aas.14439 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Acta Anaesthesiologica Scandinavica, online erschienen am 09.05.2024. Verfasst von Vladimir Kuklin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology & Intensive Care, Østfold Kalnes Hospital, Grålum, Norway. Hauptthemen laut MEDLINE: Benzodiazepines, Hypnotics and Sedatives. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Remimazolam, a novel intravenous benzodiazepine recently approved by both the European Medicines Agency and the Food and Drug Agency, shows considerable promise in clinical practice. Its pharmacodynamic profile closely resembles that of midazolam, while its pharmacokinetic properties are similar to those of remifentanil. While research in adult populations continues to accumulate, the pace of pediatric studies is not as significant. This scoping review aims to systematically examine published studies, clinical trials, observational research, case reports, and relevant literature to provide a comprehensive understanding of remimazolam in pediatric sedation and anesthesia. By synthesizing the gathered evidence, we aim to identify gaps in the literature, guide future research endeavors, and inform clinical practices.

Methods

The review follows the guidelines outlined by the Preferred Reporting Items for Systematic Review and Meta‐Analysis for Scoping Review. A thorough search strategy was implemented across prominent peer‐reviewed databases, with focused efforts to identify relevant grey literature. All primary studies involving the use of remimazolam in pediatric populations were included in this review.

Results

Eighteen studies were included in this analysis, comprising 2 randomized controlled trials, 4 prospective cohort trials, 12 case reports, and 692 children in total.

Conclusion

This scoping review highlights the increasing interest in using remimazolam as a sedative or anesthetic for children. Although initial evidence indicates its effectiveness and safety, more research is necessary to fill knowledge gaps, establish standard protocols, and optimize its use in pediatric anesthesia and sedation. Addressing these challenges will enable clinicians to improve the quality of care and outcomes for pediatric patients undergoing sedation and anesthesia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzodiazepinesHypnotics and SedativesHumansChildAnesthesiaChild, PreschoolInfantAdolescent

Stichwörter der Autor:innen

anesthesiachildrenremimazolamsedation

Substanzen

remimazolamBenzodiazepinesHypnotics and Sedatives

Autor:innen und Institutionen

  • Department of Anaesthesiology & Intensive Care, Østfold Kalnes Hospital, Grålum, Norway.
  • Department of Anaesthesiology & Intensive Care, Akershus University Hospital, Lørenskog, Norway.
  • Faculty of Medicine, Institute of Clinical Medicine, Oslo University, Oslo, Norway.

ORCID-Profile: Vladimir Kuklin, Tom G Hansen

Zitieren

APA

Kuklin, V., & Hansen, T. G. (2024). Remimazolam for sedation and anesthesia in children: A scoping review. Acta Anaesthesiologica Scandinavica, 68(7), 862-870. https://doi.org/10.1111/aas.14439

Vancouver

Kuklin V, Hansen TG. Remimazolam for sedation and anesthesia in children: A scoping review. Acta Anaesthesiologica Scandinavica. 2024;68(7):862-870. doi:10.1111/aas.14439

BibTeX
@article{Kuklin2024,
  author = {Kuklin, Vladimir and Hansen, Tom G},
  title = {Remimazolam for sedation and anesthesia in children: A scoping review},
  journal = {Acta Anaesthesiologica Scandinavica},
  year = {2024},
  volume = {68},
  number = {7},
  pages = {862--870},
  doi = {10.1111/aas.14439}
}
Kostenlos starten →